Stock IIL INTRAVENOUS INFUSIONS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Intravenous Infusions Plc

Equities

IIL

GH0000001258

Pharmaceuticals

End-of-day quote Ghana S.E.
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
0.05 GHS 0.00% Intraday chart for Intravenous Infusions Plc 0.00% 0.00%
02-15 Intravenous Infusions Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Intravenous Infusions Plc Reports Earnings Results for the Full Year Ended December 31, 2022 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 20.4 18.13 12.94 12.94 13.72 10.98
Enterprise Value (EV) 1 23.85 20.3 18.27 23.95 29.3 26.15
P/E ratio 7.47 x 6.38 x 6.85 x 9.46 x 12 x -3.11 x
Yield - 4.8% 8.8% 5.82% - -
Capitalization / Revenue 1.25 x 0.9 x 0.56 x 0.63 x 0.61 x 0.54 x
EV / Revenue 1.46 x 1 x 0.79 x 1.16 x 1.29 x 1.28 x
EV / EBITDA 5.13 x 4.37 x 6.02 x 10.1 x 16.6 x -9.9 x
EV / FCF -16.2 x -30.7 x -2.6 x -5.09 x -6.92 x 14.8 x
FCF Yield -6.17% -3.26% -38.5% -19.6% -14.5% 6.78%
Price to Book 2.05 x 1.25 x 0.73 x 0.76 x 0.75 x 0.74 x
Nbr of stocks (in thousands) 226,621 226,621 258,821 258,821 274,408 274,408
Reference price 2 0.0900 0.0800 0.0500 0.0500 0.0500 0.0400
Announcement Date 28/03/18 08/05/19 16/06/20 25/05/21 27/04/22 14/04/23
1GHS in Million2GHS
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 16.37 20.21 23.09 20.67 22.67 20.36
EBITDA 1 4.652 4.651 3.034 2.372 1.765 -2.642
EBIT 1 4.165 4.077 2.539 1.66 1.228 -3.207
Operating Margin 25.44% 20.18% 11% 8.03% 5.42% -15.76%
Earnings before Tax (EBT) 1 3.251 3.536 2.3 1.363 1.432 -3.533
Net income 1 2.731 2.843 1.871 1.451 1.146 -3.509
Net margin 16.68% 14.07% 8.1% 7.02% 5.06% -17.24%
EPS 2 0.0120 0.0125 0.007300 0.005287 0.004177 -0.0129
Free Cash Flow 1 -1.472 -0.6616 -7.026 -4.704 -4.235 1.773
FCF margin -8.99% -3.27% -30.44% -22.76% -18.68% 8.71%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - 0.003840 0.004400 0.002910 - -
Announcement Date 28/03/18 08/05/19 16/06/20 25/05/21 27/04/22 14/04/23
1GHS in Million2GHS
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 3.45 2.17 5.33 11 15.6 15.2
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.7417 x 0.4673 x 1.756 x 4.642 x 8.829 x -5.743 x
Free Cash Flow 1 -1.47 -0.66 -7.03 -4.7 -4.24 1.77
ROE (net income / shareholders' equity) 31.9% 23.3% 11.6% 8.14% 6.33% -21.2%
ROA (Net income/ Total Assets) 15.9% 10.8% 5.57% 3.06% 1.83% -4.29%
Assets 1 17.22 26.25 33.61 47.41 62.63 81.72
Book Value Per Share 2 0.0400 0.0600 0.0700 0.0700 0.0700 0.0500
Cash Flow per Share 2 0 0.0100 0 0 0 0
Capex 1 1.24 1.81 5.34 3.92 7.16 2.42
Capex / Sales 7.59% 8.98% 23.14% 18.95% 31.57% 11.89%
Announcement Date 28/03/18 08/05/19 16/06/20 25/05/21 27/04/22 14/04/23
1GHS in Million2GHS
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
INTRAVENOUS INFUSIONS PLC Stock Intravenous Infusions Plc
0.00% 944K
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 328B
ABBVIE INC. Stock AbbVie Inc.
+0.24% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.47% 243B
NOVARTIS AG Stock Novartis AG
+7.35% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-6.42% 203B
AMGEN INC. Stock Amgen Inc.
+4.23% 164B
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IIL Stock
  4. Financials Intravenous Infusions Plc